Last reviewed · How we verify

GcMAF injections (100 ng) — Competitive Intelligence Brief

GcMAF injections (100 ng) (GcMAF injections (100 ng)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator / Macrophage activator. Area: Oncology / Immunology.

phase 3 Immunomodulator / Macrophage activator Macrophage receptor (CD14/TLR4 complex proposed) Oncology / Immunology Biologic Live · refreshed every 30 min

Target snapshot

GcMAF injections (100 ng) (GcMAF injections (100 ng)) — S.LAB (SOLOWAYS). GcMAF (Gc-protein derived macrophage activating factor) activates macrophages to enhance immune surveillance and anti-tumor activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GcMAF injections (100 ng) TARGET GcMAF injections (100 ng) S.LAB (SOLOWAYS) phase 3 Immunomodulator / Macrophage activator Macrophage receptor (CD14/TLR4 complex proposed)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator / Macrophage activator class)

  1. S.LAB (SOLOWAYS) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GcMAF injections (100 ng) — Competitive Intelligence Brief. https://druglandscape.com/ci/gcmaf-injections-100-ng. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: